Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

1 Jan 2013

Abstract excerpt

Neuroendocrine prostate cancer (NEPC), also referred to as anaplastic prostate cancer, is a lethal tumor that most commonly arises in late stages of prostate adenocarcinoma (PCA) with predilection to metastasize to visceral organs. In the current study, we explore for evidence that Aurora kinase A (AURKA) and N-myc (MYCN) gene abnormalities are harbingers of treatment-related NEPC (t-NEPC). We studied primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Hippo pathway signaling and YAP/TAZ
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23358695
DOI: 10.1593/neo.121550

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate CancerPMID 23358695Read ↗

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsSemantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Molecular Foundations for Personalized Therapy in Prostate CancerSemantic proximity Read ↗

Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report.Semantic proximity Read ↗

Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate CancerSemantic proximity Read ↗

Treatment-related Neuroendocrine Prostate Carcinoma—Diagnostic and Molecular CorrelatesSemantic proximity Read ↗

Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate CancerSemantic proximity Read ↗

ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.Semantic proximity Read ↗

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read ↗

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factorsSemantic proximity Read ↗

Targeting RET Kinase in Neuroendocrine Prostate CancerSemantic proximity Read ↗

Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.